Moderate quality evidence shows reduction in frequency of hot flashes with paroxetine
TUESDAY, April 19, 2016 (HealthDay News) — For perimenopausal and postmenopausal women, paroxetine reduces vasomotor symptoms, according to a review and meta-analysis published online April 7 in BJOG: An International Journal of Obstetrics and Gynaecology.
Dang Wei, from Lanzhou University in China, and colleagues conducted a systematic review to confirm the effect and safety of paroxetine for vasomotor symptoms. Data were included from five articles with six randomized controlled trials (1,571 participants who experienced moderate-to-severe vasomotor symptoms) that compared paroxetine with placebo or no treatment.
The researchers found that at week four and week 12, paroxetine reduced the frequency of hot flashes by 8.86 and 7.36 per week, respectively (both P < 0.00001). The evidence on the effect of paroxetine was of moderate quality. The most consistently reported adverse effects were nausea, dizziness, headache, fatigue, and constipation; nausea and dizziness were 2.45- and 2.44-times higher than placebo, respectively.
“Paroxetine is effective for reducing vasomotor symptoms in menopausal women, and this finding is supported by moderate quality evidence,” the authors write. “However, nausea and dizziness are more common in women taking paroxetine than placebo.”
Women With Autism May Experience More Severe Menopause 
Oral Menopausal Hormone Therapy Linked to Venous Thromboembolic Risk 
MHT Initiation May Reduce Cardiovascular Risk in Women With Vasomotor Symptoms 
Longer Reproductive Lifespan Tied to Lower Bronchiectasis Risk in Postmenopausal Women 
Midlife Onset of Increasing Pulse Pressure Not Linked to Menopause 
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women 
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children 
Fractional Exhaled Nitric Oxide Elevated in Pediatric Chest Tightness Variant Asthma 
